SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-053981
Filing Date
2024-05-07
Accepted
2024-05-07 08:33:49
Documents
59
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q inzy-20240331.htm   iXBRL 10-Q 1136164
2 EX-10.2 inzy-ex10_2.htm EX-10.2 40018
3 EX-31.1 inzy-ex31_1.htm EX-31.1 15267
4 EX-31.2 inzy-ex31_2.htm EX-31.2 15923
5 EX-32.1 inzy-ex32_1.htm EX-32.1 8711
6 EX-32.2 inzy-ex32_2.htm EX-32.2 8837
  Complete submission text file 0000950170-24-053981.txt   5337906

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT inzy-20240331.xsd EX-101.SCH 973704
63 EXTRACTED XBRL INSTANCE DOCUMENT inzy-20240331_htm.xml XML 668308
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39397 | Film No.: 24919790
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)